Search
forLearn
5 / 801 resultslearn Osteopontin
signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss
learn ORPL
learn NMN
learn apigenina
Research
5 / 1000+ results
research A new path in defining light parameters for hair growth: Discovery and modulation of photoreceptors in human hair follicle
Blue light promotes hair growth by interacting with specific receptors in hair follicles.
research 1369 Blue light stimulatory effect on hair growth mediated by opsin and cryptochrome photoreceptors
Blue light can help hair grow by affecting certain receptors in hair follicles.
research 254 WITHDRAWN
Aging causes sweat glands to shrink, leading to skin issues, and blue light can help hair grow.
research 253 Opsins and Cryptochrome photoreceptors mediate blue light stimulatory effect on hair growth
Blue light helps hair growth by affecting specific proteins in hair follicle cells.
research 874 Elevated expression of osteopontin splice variants in nonmelanoma skin cancer compared to normal skin and adult keratinocytes
Nonmelanoma skin cancers have higher levels of certain osteopontin variants than normal skin.
Community Join
5 / 1000+ resultscommunity Amplifica and AMP-303 clinical phase 1
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.
community Published in Nature: Osteopontin, a protein involved in the growth of hair on moles could be the key to our troubles.
Osteopontin, a protein involved in hair growth on moles, may help with hair loss. However, it is also linked to Alzheimer's, cancer, and bone development, so caution is advised.
community PP405 (Non) Update - Feb 2025
The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.
community 3 month progress pictures RU fin and OM
The user shared progress pictures after three months of using RU58841, finasteride, and OM (oxidative stress modulators) for hair loss treatment. They haven't noticed much change but are seeking feedback on their results.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.